CSNK1E
CSNK1E (Casein kinase I isoform epsilon) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Follicular lymphoma.
Overview
Casein kinases are operationally defined by their preferential utilisation of acidic proteins such as caseins as substrates. Participates in Wnt signalling. Phosphorylates DVL1.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CSNK1E (Casein kinase I isoform epsilon) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Follicular lymphoma.
- 1 · What it is
CSNK1E (Casein kinase I isoform epsilon) is a protein kinase, an enzyme that switches other proteins on by adding phosphate groups. The public catalogues list it as a drug target, and an approved or late-stage drug is recorded against it. Tied to Non-Hodgkin lymphoma and Follicular lymphoma.
- 2 · What goes wrong in cancer
Casein kinases are operationally defined by their preferential utilisation of acidic proteins such as caseins as substrates. Participates in Wnt signalling.
- 3 · How drugs use it
No product in this corpus aims at CSNK1E yet. Kinases are switched on by binding ATP inside the cell, so most drugs are small molecules shaped to plug that ATP pocket.
External identifiers
Sources: HGNC HGNC:2453 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P49674 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000213923 (per-cancer scores at or above 0.5: non-Hodgkin lymphoma 0.57, follicular lymphoma 0.52 (GraphQL API, CC0))
Biology
Casein kinases are operationally defined by their preferential utilisation of acidic proteins such as caseins as substrates. Participates in Wnt signalling. Phosphorylates DVL1. Phosphorylates DVL2. Phosphorylates NEDD9/HEF1. Central component of the circadian clock. Location: Cytoplasm; Nucleus (UniProt). Locus 22q13.1 (HGNC).
- Non-Hodgkin lymphoma: Open Targets association 0.57 with non-Hodgkin lymphoma (MONDO_0018908)
- Follicular lymphoma: Open Targets association 0.52 with follicular lymphoma (MONDO_0018906)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: Open Targets known-drug datatype score 0.93. Evidence tier "approved-drug" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CSNK1E" OR ABSTRACT:"CSNK1E" OR TITLE:"casein kinase 1 epsilon" OR ABSTRACT:"casein kinase 1 epsilon" OR TITLE:"Casein kinase I isoform epsilon" OR ABSTRACT:"Casein kinase I isoform epsilon" OR TITLE:"HCKIE" OR ABSTRACT:"HCKIE" OR TITLE:"CKIepsilon" OR ABSTRACT:"CKIepsilon") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CSNK1E, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetPIK3CG
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TargetCUL4A
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TargetDDB1
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TargetRBX1
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TrialA Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types).
- TargetCD3D
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TargetCD3G
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types), Open Targets Platform.
- TrialSurovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
Shares Follicular lymphoma, Non-Hodgkin lymphoma (all types).